Download PDF
Thromb Haemost 2001; 86(05): 1296-1304
DOI: 10.1055/s-0037-1616065
Review Article
Schattauer GmbH

Thrombostatin Inhibits Cyclic Flow Variations in Stenosed Canine Coronary Arteries

Ahmed A. K. Hasan
1   Hematology/Oncology, Ann Arbor, MI, USA
6   Thromgen, Inc., Ann Arbor, MI, USA
,
Alvin H. Schmaier
1   Hematology/Oncology, Ann Arbor, MI, USA
4   Pathology, Ann Arbor, MI, USA
6   Thromgen, Inc., Ann Arbor, MI, USA
,
Mark Warnock
6   Thromgen, Inc., Ann Arbor, MI, USA
,
Daniel Normolle
5   Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI
,
Edward Driscoll
3   Pharmacology, Ann Arbor, MI, USA
,
Benedict R. Lucchesi
3   Pharmacology, Ann Arbor, MI, USA
,
Steven W. Werns
2   Cardiology Divisions, Departments of Internal Medicine, Ann Arbor, MI, USA
› Author AffiliationsThe worked was supported by NIH grant HL56415 to Dr. Schmaier and grants HL61081 and HL61981 to Dr. Hasan.
Further Information

Publication History

Received 06 October 2000

Accepted after resubmission 22 June 2001

Publication Date:
13 December 2017 (online)

Also available at
    Permissions and Reprints

Summary

Thrombostatins are a group of compounds based upon a breakdown product of bradykinin, RPPGF. They inhibit -thrombin-induced platelet activation by binding to protease activated receptor 1 and, at a lower affinity, by interacting with thrombin’s active site. After a single intravenous infusion of MAP4-RPPGF (11.58 mg/kg), its t½α was 4.5 min with a clearance of 2.0 ml/min. MAP4-RPPGF administration had a sustained antiplatelet effect, preventing γ-thrombin-induced (12.5 nM) platelet activation for 4 h. Its antiplatelet effect summated with that of aspirin and/or clopidogrel. MAP4-RPPGF was compared with aspirin and clopidogrel in the Folts model of coronary artery thrombosis. Dogs were randomized to 3 treatment groups: aspirin 1.14 mg/kg i. v., clopidogrel 0.5 mg/kg i. v., or MAP4-RPPGF 0.77 mg/kg i. v. Cyclic flow variations (CFV) were recorded in 5 untreated dogs hourly for 3 successive hours and for 1 h before (all groups >11 CFV/h), and for 2 h after drug infusion in each of the 3 treatment groups. After 1 h drug treatment, all groups of animals had <6 CFV/h; after 2 h treatment, all had <1 CFV/h. All agents significantly reduced CFV from control at each hour, but none was significantly better than any other. Thrombostatin was as effective as aspirin or clopidogrel in inhibiting coronary artery thrombosis in this canine model.

Keywords

Thrombin - platelets - coronary thrombosis - bradykinin - thrombostatin
 

  • References

  • 1 Shima C, Majima M, Katori M. A stable metabolite, Arg-Pro-Pro-Gly-Phe, of bradykinin in the degradation pathway in human plasma. Jpn J Pharmacol 1992; 60: 111-9.
    CrossrefPubMedSearch in Google Scholar
  • 2 Majima M, Sunahara N, Harada Y, Katori M. Detection of the degradation products of bradykinin by enzyme immunoassays as markers for the release of kinin in vivo. Biochem Pharmacol 1993; 45: 559-67.
    CrossrefPubMedSearch in Google Scholar
  • 3 Meloni F, Schmaier A. Low molecular weight kininogen binds to platelets to modulate thrombin-induced platelet activation. J Biol Chem 1991; 266: 6786-94.
    PubMedSearch in Google Scholar
  • 4 Jiang Y, Muller-Esterl W, Schmaier A. Domain 3 of kininogen contains a cell binding site and a site that modifies thrombin activation of platelets. J Biol Chem 1992; 267: 3712-7.
    PubMedSearch in Google Scholar
  • 5 Hasan A, Amenta S, Schmaier A. Bradykinin and its metabolite, Arg-ProPro-Gly-Phe, are selective inhibitors of alpha-thrombin-induced platelet activation. Circulation 1996; 94: 517-28.
    CrossrefPubMedSearch in Google Scholar
  • 6 Puri R, Zhou F, Hu C-J, Colman R, Colman R. High molecular weight kininogen inhibits thrombin-induced platelet aggregation and cleavage of aggregin by inhibiting binding of thrombin to platelets. Blood 1991; 77: 500-7.
    PubMedSearch in Google Scholar
  • 7 Hasan A, Rebello S, Smith E, Srikanth S, Werns S, Driscoll E, Faul J, Brenner D, Normolle D, Lucchesi B, Schmaier A. Thrombostatin inhibits induced canine coronary thrombosis. Thromb Haemost 1999; 82: 1182-7.
    Thieme ConnectPubMedSearch in Google Scholar
  • 8 Folts J, Crowell E, Rose G. Platelet aggregation in partially obstructed vessels and its elimination with aspirin. Circulation 1976; 54: 365-70.
    CrossrefPubMedSearch in Google Scholar
  • 9 Folts J, Gallagher K, Rose G. Blood flow reductions in stenosed canine coronary arteries: vasospasm or platelet aggregation?. Circulation 1982; 65: 248-55.
    CrossrefPubMedSearch in Google Scholar
  • 10 Folts J, Rose G. Epinephrine potentiation of in vivo stimuli reverses aspirin inhibition of platelet thrombus formation in stenosed canine coronary arteries. Thrombosis Research 1988; 50: 507-16.
    CrossrefPubMedSearch in Google Scholar
  • 11 Folts J. An in vivo model of experimental arterial stenosis, intimal damage, and periodic thrombosis. Circulation 1991; 83 suppl IV 3-14.
    PubMedSearch in Google Scholar
  • 12 Folts J, Schafer A, Loscalzo J, Willerson J, Muller J. A perspective on the potential problems with aspirin as an antithrombotic agent: a comparison of studies in an animal model with clinical trials. J Am Coll Cardiol 1999; 33: 295-303.
    CrossrefPubMedSearch in Google Scholar
  • 13 Rebello S, Blank HS, Rote WE, Vlasuk GP, Lucchesi BR. Antithrombotic efficacy of a recombinant nematode anticoagulant peptide (rNAP5) in canine models of thrombosis after single subcutaneous administration. J Pharm Exp Therap 1997; 283: 91-9.
    PubMedSearch in Google Scholar
  • 14 Gailani D, Broze G. Factor XI activation in a revised model of blood coagulation. Science 1991; 25: 909-12.
    PubMedSearch in Google Scholar
  • 15 Alpert A. Hydrophobic interaction chromatography of peptides as an alternative to reversed-phase chromatography. J Chromatogr 1988; 444: 269-74.
    CrossrefPubMedSearch in Google Scholar
  • 16 Rowland M, Tozer T. Clinical pharmacokinetics: concepts and application. 2nd Edition. Philadelphia: Lea & Febiger; 1989
    Search in Google Scholar
  • 17 Bush L, Campbell W, Kern K, Tilton G, Apprill P, Ashton J, Schmitz J, Buja L, Willerson J. The effects of alpha-2-adrenergic and serotonergic receptor antagonists on cyclic blood flow alterations in stenosed canine coronary arteries. Circ Res 1984; 55: 642-52.
    CrossrefPubMedSearch in Google Scholar
  • 18 Coller B, Folts J, Scudder L, Smith S. Antithrombotic effect of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor in an experimental animal model. Blood 1986; 68: 783-6.
    PubMedSearch in Google Scholar
  • 19 Yao S-K, Ober J, McNatt J, Benedict C, Rosolowky M, Anderson H, Cui K, Maffrand J, Campbell W, Buja L, Willerson J. ADP plays an important role in mediating platelet aggregation and cyclic flow variations in vivo in stenosed and endothelium-injured canine coronary arteries. Circ Res 1992; 70: 39-48.
    CrossrefPubMedSearch in Google Scholar
  • 20 McCullagh P, Nelder J. Generalized linear models. Second edition Chapman and Hall; London: 1989
    Search in Google Scholar
  • 21 Lynch J, Cook J, Sitko G, Holahan M, Ramjit D, Mellott M, Stranieri M, Stabilito I, Zhang G, Lynch R, Manno P, Chang C, Egbertson M, Haldzenko W, Duggan M, Laswell W, Vassallo L, Shafer J, Anderson P, Friedman P, Hartman G, Gould R. Nonpeptide glycoprotein IIb/IIIa inhibitors. Anti-thrombotic effects of MK-0383. J Pharmcol Exp Therap 1995; 272: 20-32.
    PubMedSearch in Google Scholar
  • 22 Eichhorn E, Grayburn P, Willard J, Anderson H, Bedotto J, Carry M, Kahn J, Willerson J. Spontaneous alterations in coronary blood flow velocity before and after coronary angioplasty in patients with severe angina. J Am Coll Cardiol 1991; 17: 43-52.
    CrossrefPubMedSearch in Google Scholar
  • 23 Anderson H, Kirkeeide R, Krishnaswami A, Weigelt L, Revana M, Weisman H, Willerson J. Cyclic flow variations after coronary angioplasty in humans: clinical and angiographic characteristics and elimination with 7E3 monoclonal antiplatelet antibody. J Am Coll Cardiol 1994; 23: 1031-7.
    CrossrefPubMedSearch in Google Scholar